Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views

被引:4
|
作者
Connor, Susan J. [1 ]
Sechi, Alexandra [2 ]
Andrade, Mauricio [3 ]
Deuring, J. Jasper [4 ]
Witcombe, David [3 ]
机构
[1] Univ New South Wales, Liverpool Hosp, South Western Sydney Clin Sch, Dept Gastroenterol,Ingham Inst Appl Med Res, Liverpool, NSW, Australia
[2] Liverpool Hosp, Dept Gastroenterol, Liverpool, NSW, Australia
[3] Pfizer Australia, Sydney, NSW, Australia
[4] Pfizer Inc, Rotterdam, Netherlands
来源
JGH OPEN | 2021年 / 5卷 / 09期
关键词
communication; survey; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; SELF-MANAGEMENT; SATISFACTION; INTERVENTIONS; COMMUNICATION; PERSPECTIVE; PREVALENCE; KNOWLEDGE; IMPACT;
D O I
10.1002/jgh3.12627
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: The Global Ulcerative Colitis (UC) Narrative Survey aimed to evaluate the impact of UC, perceptions of UC burden, and management approaches. Here, we present data from patients and physicians in Australia. Methods: Surveys, fielded by The Harris Poll, were completed by 215 patients with UC and 90 physicians, between August 2017 and February 2018. Surveys included questions on disease characteristics, impact on life, communication with physicians, and patient knowledge of UC. Results are presented descriptively from all respondents (with no imputation for missing data). Results: Based on medication history, 84% of patients had moderate to severe UC. Diagnostic delay was on average 1.9 (SD 5.0) years and 48% of patients had waited >= 1 year for diagnosis. Nearly two-thirds (65%) of patients considered themselves to be in remission, with 97% also reporting a flare in the past year. The majority (92%) of patients were satisfied with their UC medication and, if their treatment made them feel "good enough," many (75%) would not consider an alternative. Most (90%) patients were satisfied with communication with their physician; however, only 48% felt comfortable raising emotional concerns. Both patients and physicians desired more time during routine appointments. Patients had gaps in their knowledge of UC, which physicians mostly recognized. Conclusions: The Australian survey results highlighted the diagnostic delay and burden of UC patients' experience, gaps in patients' knowledge of UC, and challenges in patient-physician communication. Compared with the overall Global UC Narrative Survey, patients in Australia reported a high burden of disease.
引用
收藏
页码:1033 / 1040
页数:8
相关论文
共 25 条
  • [21] Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey
    Danese, Silvio
    Hoffman, Camille
    Vel, Senthil
    Greco, Marco
    Szabo, Hajnalka
    Wilson, Ben
    Avedano, Luisa
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (12) : 1385 - 1391
  • [22] Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease
    Ginard, Daniel
    Ricote, Mercedes
    Nos, Pilar
    Pejenaute, M. Elena
    Sans, Miquel
    Fontanillas, Noelia
    Acosta, Manuel Barreiro-de
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (08): : 647 - 656
  • [23] Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic
    Sergio Pinto
    Erica Loddo
    Salvatore Paba
    Agnese Favale
    Fabio Chicco
    Sara Onali
    Paolo Usai
    Massimo Claudio Fantini
    Journal of Patient-Reported Outcomes, 5
  • [24] Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic
    Pinto, Sergio
    Loddo, Erica
    Paba, Salvatore
    Favale, Agnese
    Chicco, Fabio
    Onali, Sara
    Usai, Paolo
    Fantini, Massimo Claudio
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2021, 5 (01)
  • [25] Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
    Ko, Yanna
    Paramsothy, Sudarshan
    Yau, Yunki
    Leong, Rupert W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) : 292 - 301